Risk of tuberculosis with anti‐tumor necrosis factor‐α therapy: substantially higher number of patients at risk in Asia
Authors:
Open Access
- 16 October 2013
- journal article
- research article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 17 (3) , 291-298
Abstract
Aim: To assess the potential risk of tuberculosis (TB) in patients treated with anti‐tumor necrosis factor‐alpha (TNF‐α) agents in Asia.Methods: Absolute risk increase (ARI) of TB was estimated for three widely used anti‐TNF‐α therapies using published standardized incidence ratios (SIR) from the French Research Axed on Tolerance of bIOtherapies registry and incidence (absolute risk [AR]) of TB in Asia. Assuming an association of increased TB risk with anti‐TNF‐α therapy and country TB AR (incidence), the ARI of TB by country was calculated by multiplying the SIR of the anti‐TNF‐α therapy by the country's TB AR. The numbers needed to harm (NNH) for each anti‐TNF‐α agent and numbers needed to treat (NNT) to reduce one TB event using etanercept therapy instead of adalimumab or infliximab were also calculated for each country.Results: The ARI of TB with anti‐TNF‐α therapies in Asian countries is substantially higher than Western Europe and North America and the difference between etanercept versus the monoclonal antibodies becomes more evident. The NNH for Asian countries ranged from 8 to 163 for adalimumab, 126 to 2646 for etanercept and 12 to 256 for infliximab. The NNT to reduce one TB event using etanercept instead of adalimumab therapy ranged from 8 to 173, and using etanercept instead of infliximab therapy the NNT ranged from 13 to 283.Conclusion: Higher numbers of patients are at risk of developing TB with anti‐TNF‐α therapy in Asia compared with Western Europe and North America. The relative lower risk of TB with etanercept may be particularly relevant for Asia, an endemic area for TB.Keywords
This publication has 35 references indexed in Scilit:
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of RheumatologyClinical Rheumatology, 2010
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Annals of the Rheumatic Diseases, 2010
- Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registryArthritis & Rheumatism, 2009
- Show Me the Evidence: Using Number Needed to TreatSouthern Medical Journal, 2007
- Binding Characteristics of Tumor Necrosis Factor Receptor-Fc Fusion Proteins vs Anti-Tumor Necrosis Factor mAbsJournal of Investigative Dermatology Symposium Proceedings, 2007
- The efficacy of infliximab for patients with rheumatoid arthritis in Japan: results of 5000 cases by post-marketing surveillance dataInternational Journal of Rheumatic Diseases, 2006
- Number needed to treat (NNT): implication in rheumatology clinical practiceAnnals of the Rheumatic Diseases, 2003
- Individualizing Treatment DecisionsEvaluation & the Health Professions, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001